Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

David Bartlett, MA Preece, E Holme, C Lloyd, Philip Newsome, Patrick McKiernan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: Tyrosinaemia type 1 (HT1) is a rare disorder leading to accumulation of toxic metabolites such as succinylacetone (SA) and a high risk of hepatocellular carcinoma. Children with HT1 traditionally required liver transplantation (OLT) and while the need for this has been reduced by the introduction of nitisinone some still require OLT. SA inhibits the enzyme porphobilinogen (PBG) synthase and its activity can be used as a marker of active SA. Elevated urinary SA post OLT has been reported previously. This study describes a novel finding of elevated plasma SA following OLT for HT1. METHODS: A retrospective analysis was performed of patients treated for HT1 at our institution from 1989-2010. RESULTS: Thirteen patients had an OLT for HT1. In patients who received nitisinone prior to OLT, mean urinary and plasma SA were elevated prior to treatment but normalised by the time of OLT (p ≤ 0.01). Mean PBG synthase activity increased from 0.032 to 0.99 nkat/gHb (ref range 0.58-1.25) at the time of OLT (p 
Original languageEnglish
JournalJournal of Inherited Metabolic Disease
DOIs
Publication statusPublished - 29 Mar 2012

Fingerprint

Dive into the research topics of 'Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.'. Together they form a unique fingerprint.

Cite this